Local effects of malignancy on bone

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 6, 2007, Pages 436-441

  Brown, Sue A ^a,b   Clines, Gregory A ^a   Guise, Theresa A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE   (United States)

Author keywords

Bisphosphonates; Bone; Cancer; Metastases

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CELL PROTEIN; ENDOTHELIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN DICKKOPF 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT1 PROTEIN;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER SURVIVAL; CELL ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; ENDOTHELIN-1; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MULTIPLE MYELOMA; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEINS;

EID: 35848946353     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f15419     Document Type: Article

References (41)

1. Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003; 20:171-180.
2. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12:6213s-6216s.
3. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537-549.
4. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts: a cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 2002; 277:21352-21360.
5. Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002; 277:24571-24578.
6. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005; 102:13909-13914.
7. Pratap J, Lian JB, Javed A, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006; 25:589-600. This review considers the evidence that Runx2 regulates early metastatic events in breast and prostate cancer.
8. Javed A, Barnes GL, Pratap J, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A 2005; 102:1454-1459.
9. Lipton A, Berenson JR, Body JJ, et al. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res 2006; 12:6209s-6212s. This concise summary from an international conference provides an overview of the direction of research in therapeutic strategies for metastatic bone cancer.
10. Bandyopadhyay A, Agyin JK, Wang L, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006; 66:6714-6721.
11. Stebbins EG, Mohammad KS, Niewolna M, et al. SD-208, a small molecule inhibitor of transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of beast cancer cells. J Bone Miner Res 2005; 20:S55.
12. Javelaud D, Mohammad KS, McKenna CR, et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 2007; 67:2317-2324. This original research indicates that TGF-β promotes metastases to bone by melanoma.
13. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007; 171:1047-1057. This paper presents evidence that BMP-7 may be a novel therapeutic target for treatment of metastatic bone disease.
14. Roodman GD. New potential targets for treating myeloma bone disease. Clin Cancer Res 2006; 12:6270s-6273s. This is a comprehensive review detailing progress toward targeting novel pathways in multiple myeloma bone disease.
15. Vela I, Gregory L, Gardiner EM, et al. Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU Int 2007; 99:735-742.
16. Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005; 7:485-496.
17. Yonou H, Horiguchi Y, Ohno Y, et al. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts. Prostate 2007; 67:840-848.
18. Chen G, Sircar K, Aprikian A, et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107:289-298.
19. Mountzios G, Dimopoulos MA, Bamias A, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol 2007; 46:221-229.
20. Zheng Y, Zhou H, Brennan K, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the antitumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007; 40:471-478.
21. Holmen SL, Giambernardi TA, Zylstra CR, et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res 2004; 19:2033-2040.
22. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483-2494.
23. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135:688-692.
24. Yamabuki T, Takano A, Hayama S, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007; 67:2517-2525.
25. Clines GA, Mohammad KS, Bao Y, et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007; 21:486-498. This original research shows that tumor-produced ET-1 mediates osteoblastic metastases via suppression of the Wnt inhibitor DKK1.
26. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003; 100:10954-10959.
27. Schwaninger R, Rentsch CA, Wetterwald A, et al. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol 2007; 170:160-175.
28. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21:679-689.
29. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12:6296s-6300s. This article provides a review of endothelins and their receptor antagonists in prostate cancer bone metastases.
30. Nelson JB. Endothelin receptor antagonists. World J Urol 2005; 23:19-27.
31. Hiraga T, Kizaka-Kondoh S, Hirota K, et al. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007; 67:4157-4163.
32. Moolenaar WH. Development of our current understanding of bioactive lysophospholipids. Ann N Y Acad Sci 2000; 905:1-10.
33. Boucharaba A, Serre CM, Gres S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114:1714-1725.
34. Boucharaba A, Serre CM, Guglielmi J, et al. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 2006; 103:9643-9648. This original study indicates a new target for bone metastases treatment by targeting the LPA receptor.
35. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
36. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98:1735-1744.
37. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006; 8:R13. This multinational study followed patients given oral clodronate for breast cancer and reported increased bone relapse-free 5-year survival.
38. Lein M, Wirth M, Miller K, et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol 2007; 20 February [Epub ahead of print].
39. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935.
40. Guise TA. Do markers of bone turnover predict clinical outcome in patients with bone metastases? Nat Clin Pract Endocrinol Metab 2006; 2:258-259.
41. Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E. Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. J Urol 2007; 12 July [Epub ahead of print].